Spain’s Royal Decree 903: Medical Cannabis Is Legal but Only in Hospitals — Here’s Why Pharmacies Are Fighting Back

Spain’s medical cannabis is finally legal — but why can’t you get it from your local pharmacy?

Spain medical cannabis 2026 has arrived — but not in the way patients and pharmacists expected. On October 7, 2025, the Spanish Council of Ministers approved Royal Decree 903/2025, establishing the country’s first comprehensive legal framework for cannabis-based medicines. The decree represents a watershed moment for Europe’s largest per-capita cannabis consumer, yet the regulations have already sparked two Supreme Court appeals from pharmacy associations who argue that restricting dispensing exclusively to hospitals will leave thousands of patients without adequate access.

This analysis breaks down what Royal Decree 903 establishes, why the hospital-only rule is proving so controversial, and what the ongoing legal fight means for Spain medical cannabis 2026 and the broader European market.

What Royal Decree 903/2025 Actually Establishes

Royal Decree 903 cannabis regulations create a tightly controlled framework that permits medical cannabis only as standardized compounded formulations — known in Spanish law as “master formulas” (fórmulas magistrales). The decree explicitly excludes unprocessed cannabis flower, limiting treatment options to oily oral solutions with preset concentrations of THC (5–150 mg/ml) and CBD (10–150 mg/ml) suspended in medium-chain triglyceride (MCT) oil.

The Spanish Agency for Medicines and Health Products (AEMPS) serves as the central regulatory authority. In January 2026, the agency formally included these cannabis preparations in Spain’s National Formulary under code FN/2026/FMT/043, setting maximum daily adult doses at 32.4 mg THC and 25 mg/kg body weight for CBD.

Approved Medical Indications

Only four clinical indications qualify under the decree, and only when conventional treatments have failed:

• Spasticity due to multiple sclerosis
• Severe refractory epilepsy
• Chemotherapy-induced nausea and vomiting
• Chronic refractory pain

The AEMPS retains authority to expand this list as new clinical evidence emerges and the agency publishes formal clinical monographs — documents that were due by January 9, 2026, a deadline that was reportedly missed.

Who Can Prescribe

Spain cannabis prescription authority is restricted to specialist physicians — oncologists, neurologists, pain specialists, and select other hospital-based doctors — working within the Spanish National Health System (SNS). Primary care physicians and private practitioners are excluded entirely. This means patients must first be referred to a hospital specialist before they can even be considered for cannabis-based treatment.

The Hospital-Only Dispensing Rule: Why It’s Controversial

At the heart of the growing conflict is Article 8 of Royal Decree 903, which mandates that cannabis preparations may only be supplied to legally established Hospital Pharmacy services. Under this rule, hospital pharmacies hold exclusive responsibility for compounding cannabis-based master formulas from standardized preparations and dispensing them to both inpatients and outpatients.

Spain cannabis hospital only dispensing creates a practical access problem. Spain has approximately 800 public hospitals with pharmacy services, compared to more than 22,000 community pharmacies distributed across every town and rural area. For patients in remote regions of Andalusia, Castilla-La Mancha, or Extremadura, reaching a hospital pharmacy could mean hours of travel — a significant burden for people already managing chronic pain, epilepsy, or the side effects of chemotherapy.

The Ministry of Health has acknowledged this gap, indicating that mechanisms for remote dispensing may be introduced in “exceptional cases of vulnerability, dependency, or geographical barriers.” However, no specific regulatory framework for remote dispensing has been published as of March 2026.

One positive aspect: because dispensing occurs through hospital pharmacies, patients covered by the SNS will not bear any out-of-pocket costs for their cannabis prescriptions.

Pharmacies Are Fighting Back: Two Supreme Court Appeals

The pharmacy sector has responded with legal action. Two separate contentious-administrative appeals have been filed with Spain’s Supreme Court, both targeting Article 8 of the decree.

CEOFA — First to Challenge

The Andalusian Confederation of Pharmacy Offices (CEOFA) filed the first appeal in mid-December 2025, arguing that the decree:

• Violates the principle of normative hierarchy — contradicting existing provisions of Spain’s Law on Guarantees and Rational Use of Medicines
• Undermines territorial equity — particularly harming rural patients in southern Spain

CEOFA stated publicly that “the network of community pharmacies guarantees accessibility, territorial equity, and close, professional pharmaceutical care, especially in rural areas or those with limited healthcare resources.”

CGCOF — 22,000 Pharmacies Demand Inclusion

Weeks later, the General Council of Official Colleges of Pharmacists (CGCOF), representing all 22,000 community pharmacies in Spain, filed its own Supreme Court appeal following the decree’s publication in the Official State Gazette on January 3, 2026. The CGCOF’s core argument is straightforward: there is no health, legal, or safety justification for preventing community pharmacies from compounding and dispensing cannabis-based medications — a function they already perform for other controlled substances.

The outcome of these appeals could fundamentally reshape Spain medical cannabis 2026 implementation. If the Supreme Court rules in favor of the pharmacy associations, the government would need to amend the decree to allow community pharmacy participation, potentially accelerating patient access across the country.

Patient Access: The Real-World Impact

For the estimated hundreds of thousands of Spanish patients who could benefit from medical cannabis, Royal Decree 903 represents both a breakthrough and a frustration.

The breakthrough: Spain medical cannabis 2026 is now legal, covered by the national health system, and regulated with clear quality and safety standards. Patients with qualifying conditions have a legitimate pathway to access cannabis-based treatments for the first time.

The frustration: The pathway is narrow. Patients must:

1. Be referred to a hospital specialist (no primary care access)
2. Demonstrate that conventional treatments have failed
3. Receive a prescription from an SNS-affiliated specialist
4. Collect their medication exclusively from a hospital pharmacy

Patient advocacy groups have described the framework as restrictive and disappointing. The exclusion of cannabis flower — widely used in other European medical programs — further limits treatment options for patients who may respond better to inhaled or vaporized formulations.

Meanwhile, Spain’s approximately 800 cannabis social clubs continue to operate in a legal grey area. Royal Decree 903 does not address these organizations, leaving their members in regulatory limbo even as the hospital-only medical framework takes shape.

What This Means for the Broader Spanish Cannabis Market

Royal Decree 903 positions Spain as one of Europe’s newest medical cannabis markets, but the restrictive framework may limit its near-term commercial potential.

Implementation Timeline

The delayed AEMPS clinical monographs are a significant bottleneck. Without these documents, hospitals lack the detailed guidance they need on dosage protocols, monitoring requirements, and prescription conditions. Until the monographs are published, the practical rollout of Spain medical cannabis 2026 remains stalled.

European Context

Spain’s approach stands in stark contrast to Germany, which moved cannabis prescriptions into community pharmacies with its 2024 cannabis reform. While Spain centralizes control in hospitals, Germany decentralized — and the early data suggests German patients have benefited from greater accessibility.

Other European markets are watching closely. Portugal, Italy, the Czech Republic, and the Netherlands all have medical cannabis frameworks with varying degrees of pharmacy involvement. Spain’s Supreme Court decisions could set a precedent that influences how other Southern European nations structure their own programs.

Compliance Implications for European Cannabis Producers

For cannabis producers and GMP manufacturers looking to supply the Spanish market, Royal Decree 903 introduces rigorous compliance requirements:

• AEMPS Registry: All standardized cannabis preparations must be registered in the AEMPS public registry with strict controls on THC/CBD content, production quality, and full traceability
• GMP Standards: Manufacturing must meet pharmaceutical-grade quality standards
• Batch Documentation: Hospital pharmacy compounding requires detailed batch records for each master formula preparation
• Supply Chain Traceability: End-to-end tracking from cultivation through manufacturing to hospital pharmacy delivery

These requirements align closely with seed-to-sale compliance tracking systems. Platforms like cannabis compliance software from GrowerIQ are designed to provide the traceability, batch documentation, and quality assurance reporting that European regulators increasingly demand.

For operators already serving — or planning to enter — Spain’s cannabis social club market, GrowerIQ’s cannabis social club software offers member management and inventory tracking tools built for the European regulatory environment.

Frequently Asked Questions

Operating in Spain’s Medical Cannabis Market?

GrowerIQ’s compliance platform supports AEMPS reporting and EU-GMP requirements for Spanish licensed producers.

REQUEST DEMO